Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency
Author Information
Author(s): Simoens Steven
Primary Institution: Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven
Hypothesis
This study aims to conduct a literature review to provide insight into the drivers of orphan drug pricing and reimbursement.
Conclusion
There is a need for a transparent and evidence-based approach towards orphan drug pricing and reimbursement.
Supporting Evidence
- Orphan drugs benefit from a period of marketing exclusivity, leading to high prices.
- Pricing of orphan drugs is influenced by the limited negotiating power of payers and patients.
- Countries have different pricing and reimbursement policies for orphan drugs, affecting access and utilization.
Takeaway
Orphan drugs are very expensive because they are for rare diseases, and there aren't many patients to share the cost. We need to be clear about how we decide their prices.
Methodology
The study conducted a literature review to analyze the pricing and reimbursement of orphan drugs.
Potential Biases
Manufacturers may create monopolistic market conditions by artificially splitting diseases into sub-diseases.
Limitations
High-quality evidence about clinical added value of orphan drugs is rarely available at the time of marketing authorization due to the low number of patients.
Participant Demographics
The study discusses orphan drugs affecting a small number of patients with rare diseases.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website